Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Henk M. Lokhorst; Ingo Schmidt-Wolf; Pieter Sonneveldbronno Van Der Holt; Hans Martin; Rene Barge; Uta Bertsch; Jana Schlenzka; Gerard M.J. Bos; Sandra Croockewit; Sonja Zweegman; Iris Breitkreuz; Peter Joosten; Christof Scheid; Marinus Van Marwijk-Kooy; Hans Juergen Salwender; Marinus H.J. Van Oers; Ron Schaafsma; Ralph Naumann; Harm Sinnige; Igor Blau; Gregor Verhoef; Okke De Weerdt; Pierre Wijermans; Shulamiet Wittebol; Ulrich Duersen; Edo Vellenga; Hartmut Goldschmidt

doi:10.3324/haematol.11644

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Henk M. Lokhorst^*
, Ingo Schmidt-Wolf
, Pieter Sonneveldbronno Van Der Holt
, Hans Martin
, Rene Barge
, Uta Bertsch
, Jana Schlenzka
, Gerard M.J. Bos
, Sandra Croockewit
, Sonja Zweegman
, Iris Breitkreuz
, Peter Joosten
, Christof Scheid
, Marinus Van Marwijk-Kooy
, Hans Juergen Salwender
, Marinus H.J. Van Oers
, Ron Schaafsma
, Ralph Naumann
, Harm Sinnige
, Igor Blau

Gregor Verhoef, Okke De Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, Hartmut Goldschmidt

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

134 Citations (Scopus)

46 Downloads (Pure)

Abstract

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m² response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

Original language	English
Pages (from-to)	124-127
Number of pages	4
Journal	Haematologica
Volume	93
Issue number	1
DOIs	https://doi.org/10.3324/haematol.11644
Publication status	Published - Jan-2008

Keywords

Thalidomide
Untreated multiple myeloma

Access to Document

10.3324/haematol.11644

4696-Article Text-18735-1-10-20200722Final publisher's version, 91.9 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Lokhorst, H. M., Schmidt-Wolf, I., Van Der Holt, P. S., Martin, H., Barge, R., Bertsch, U., Schlenzka, J., Bos, G. M. J., Croockewit, S., Zweegman, S., Breitkreuz, I., Joosten, P., Scheid, C., Van Marwijk-Kooy, M., Salwender, H. J., Van Oers, M. H. J., Schaafsma, R., Naumann, R., Sinnige, H., ... Goldschmidt, H. (2008). Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 93(1), 124-127. https://doi.org/10.3324/haematol.11644

@article{f194fb7598e447bfb491ce3236cc4375,

title = "Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma",

abstract = "In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72\% vs. 54\%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m2 response was comparable in both arms, 76\% and 79\% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49\% vs. 32\%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.",

keywords = "Thalidomide, Untreated multiple myeloma",

author = "Lokhorst, \{Henk M.\} and Ingo Schmidt-Wolf and \{Van Der Holt\}, \{Pieter Sonneveldbronno\} and Hans Martin and Rene Barge and Uta Bertsch and Jana Schlenzka and Bos, \{Gerard M.J.\} and Sandra Croockewit and Sonja Zweegman and Iris Breitkreuz and Peter Joosten and Christof Scheid and \{Van Marwijk-Kooy\}, Marinus and Salwender, \{Hans Juergen\} and \{Van Oers\}, \{Marinus H.J.\} and Ron Schaafsma and Ralph Naumann and Harm Sinnige and Igor Blau and Gregor Verhoef and \{De Weerdt\}, Okke and Pierre Wijermans and Shulamiet Wittebol and Ulrich Duersen and Edo Vellenga and Hartmut Goldschmidt",

year = "2008",

month = jan,

doi = "10.3324/haematol.11644",

language = "English",

volume = "93",

pages = "124--127",

journal = "Haematologica",

issn = "0390-6078",

publisher = "FERRATA STORTI FOUNDATION",

number = "1",

}

Lokhorst, HM, Schmidt-Wolf, I, Van Der Holt, PS, Martin, H, Barge, R, Bertsch, U, Schlenzka, J, Bos, GMJ, Croockewit, S, Zweegman, S, Breitkreuz, I, Joosten, P, Scheid, C, Van Marwijk-Kooy, M, Salwender, HJ, Van Oers, MHJ, Schaafsma, R, Naumann, R, Sinnige, H, Blau, I, Verhoef, G, De Weerdt, O, Wijermans, P, Wittebol, S, Duersen, U, Vellenga, E & Goldschmidt, H 2008, 'Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma', Haematologica, vol. 93, no. 1, pp. 124-127. https://doi.org/10.3324/haematol.11644

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. / Lokhorst, Henk M.; Schmidt-Wolf, Ingo; Van Der Holt, Pieter Sonneveldbronno et al.
In: Haematologica, Vol. 93, No. 1, 01.2008, p. 124-127.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

AU - Lokhorst, Henk M.

AU - Schmidt-Wolf, Ingo

AU - Van Der Holt, Pieter Sonneveldbronno

AU - Martin, Hans

AU - Barge, Rene

AU - Bertsch, Uta

AU - Schlenzka, Jana

AU - Bos, Gerard M.J.

AU - Croockewit, Sandra

AU - Zweegman, Sonja

AU - Breitkreuz, Iris

AU - Joosten, Peter

AU - Scheid, Christof

AU - Van Marwijk-Kooy, Marinus

AU - Salwender, Hans Juergen

AU - Van Oers, Marinus H.J.

AU - Schaafsma, Ron

AU - Naumann, Ralph

AU - Sinnige, Harm

AU - Blau, Igor

AU - Verhoef, Gregor

AU - De Weerdt, Okke

AU - Wijermans, Pierre

AU - Wittebol, Shulamiet

AU - Duersen, Ulrich

AU - Vellenga, Edo

AU - Goldschmidt, Hartmut

PY - 2008/1

Y1 - 2008/1

N2 - In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m2 response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

AB - In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m2 response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

KW - Thalidomide

KW - Untreated multiple myeloma

U2 - 10.3324/haematol.11644

DO - 10.3324/haematol.11644

M3 - Article

C2 - 18166796

AN - SCOPUS:38549144944

SN - 0390-6078

VL - 93

SP - 124

EP - 127

JO - Haematologica

JF - Haematologica

IS - 1

ER -

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this